CiprianiAFurukawaTASalantiG, et al. (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet391: 1357–1366.
2.
HamiltonM (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol6: 278–296.
3.
HansenRGaynesBThiedaP, et al. (2008) Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv59: 1121–1130.
4.
HengartnerMP (2020) How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding. Ther Adv Psychopharmacol10: 1–10.
5.
HieronymusFEmilssonJFNilssonS, et al. (2016) Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry21: 523–530.
6.
JarrettRBMinhajuddinAGershenfeldH, et al. (2013) Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo. JAMA Psychiatry70: 1152–1160.
7.
KirschIDeaconBJHuedo-MedinaTB, et al. (2008) Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Med5:e45.
8.
LeuchtSHierlSKisslingW, et al. (2012) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry200: 97–106.
9.
LewisGDuffyLAdesA, et al. (2019) The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): A pragmatic, double-blind, placebo-controlled randomised trial. Lancet Psychiatry6: 903–914.
10.
MontgomerySAAsbergM (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry134: 382–389.
11.
RosenbaumJFFavaMHoogSL, et al. (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry44: 77–87.
12.
RushAJTrivediMHWisniewskiSR, et al. (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 354:1231–1242.
